cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.26886111
title: Exploring the roles and therapeutic implications of melatonin-mediated KLF6 in the development of intracranial aneurysm

description: Intracranial aneurysm (IA) is a cerebrovascular disease with a high mortality rate due to ruptured subarachnoid hemorrhage. While Krüppel-like factor 6 (KLF6) dysregulation has been implicated in cancer and cardiovascular diseases, its role in IA remains unclear. The GSE122897 and GSE15629 datasets were downloaded from the Gene Expression Omnibus database. Immune cell infiltration and hypoxia analysis were performed to explore the effects of KLF6 on IA. Weighted gene co-expression network analysis was used to identify hub genes related to KLF6 expression for subsequent analyses. Hypoxia-related genes were identified. Drug prediction was performed for IA. Samples from healthy individuals and patients with IA were collected to detect the expression of endothelin-1 (ET-1), vascular hematoma factor (vWF), and KLF6. A model of H<sub>2</sub>O<sub>2</sub>-induced human brain vascular smooth muscle cells (HBVSMC) injury was constructed to explore the effects of KLF6 and melatonin to treat IA. T cells CD4 memory resting and monocytes were significantly different in the KLF6 high and low expression groups. Four hypoxia-related gene sets were significantly enriched in the KLF6 high-expression group. Six hypoxia-related hub genes were obtained, which were significantly associated with KLF6. Drug prediction showed that melatonin may be a potential drug for IA. The levels of ET-1, vWF, and KLF6 were significantly upregulated in patients with IA. KLF6 exacerbates H<sub>2</sub>O<sub>2</sub>-induced injury in HBVSMC, ameliorated by melatonin. KLF6 may be a potential target for IA treatment, with melatonin-mediated KLF6 effects playing a crucial role in the development of IA. KLF6 was associated with infiltrated immune cells and hypoxia genes in intracranial aneurysm.KLF6 was significantly upregulated in patients with intracranial aneurysm.KLF6 exacerbates H<sub>2</sub>O<sub>2</sub>-induced injury in HBVSMC, ameliorated by melatonin. KLF6 was associated with infiltrated immune cells and hypoxia genes in intracranial aneurysm. KLF6 was significantly upregulated in patients with intracranial aneurysm. KLF6 exacerbates H<sub>2</sub>O<sub>2</sub>-induced injury in HBVSMC, ameliorated by melatonin.
DOI: 10.6084/m9.figshare.27203407
title: Investigation of gut microbiota disorders in norovirus infected children patients based on 16s rRNA sequencing

description: Norovirus is the leading cause of sporadic viral gastroenteritis cases and outbreaks. Gut microbiota plays a key role in maintaining immune homeostasis. We aimed to investigate the composition and functional effects of gut microbiota in children infected with norovirus. Stool samples were collected from 31 children infected with norovirus and 25 healthy children. The gut microbiota was analyzed by 16S rRNA gene sequencing, followed by composition, correlation network, functional and phenotype prediction analyses. Gut microbiota in children infected with norovirus was characterized by lower species richness and diversity. <i>Veillonella</i> is the dominant gut microbiota specie in norovirus infection. <i>Blautia</i> was significantly lower in norovirus infection. There was a positive correlation between <i>Faecalibacterium</i>, <i>Blautia</i>, <i>Subdoligranulum</i>, <i>Eubacterium_hallii_group</i>, <i>Fusicatenibacter</i>, <i>Agathobacter</i>, <i>Roseburia</i> and <i>Dorea</i>. Functionally, secondary metabolites biosynthesis, transport and catabolism, selenocysteine lyase and peroxiredoxin were the most significantly higher functional compositions of gut microbiota in norovirus infection. However, sn-glycerol-1-phosphate dehydrogenase and fermentation were the most significantly lower functional compositions in norovirus infection group. Phenotype analysis showed that Contains_Mobile_Elements had the highest level of phenotypes in the gut microbiota of norovirus infection. Norovirus infection may lead to dysregulation of the gut microbiome in children.
DOI: 10.6084/m9.figshare.27203407.v1
title: Investigation of gut microbiota disorders in norovirus infected children patients based on 16s rRNA sequencing

description: Norovirus is the leading cause of sporadic viral gastroenteritis cases and outbreaks. Gut microbiota plays a key role in maintaining immune homeostasis. We aimed to investigate the composition and functional effects of gut microbiota in children infected with norovirus. Stool samples were collected from 31 children infected with norovirus and 25 healthy children. The gut microbiota was analyzed by 16S rRNA gene sequencing, followed by composition, correlation network, functional and phenotype prediction analyses. Gut microbiota in children infected with norovirus was characterized by lower species richness and diversity. <i>Veillonella</i> is the dominant gut microbiota specie in norovirus infection. <i>Blautia</i> was significantly lower in norovirus infection. There was a positive correlation between <i>Faecalibacterium</i>, <i>Blautia</i>, <i>Subdoligranulum</i>, <i>Eubacterium_hallii_group</i>, <i>Fusicatenibacter</i>, <i>Agathobacter</i>, <i>Roseburia</i> and <i>Dorea</i>. Functionally, secondary metabolites biosynthesis, transport and catabolism, selenocysteine lyase and peroxiredoxin were the most significantly higher functional compositions of gut microbiota in norovirus infection. However, sn-glycerol-1-phosphate dehydrogenase and fermentation were the most significantly lower functional compositions in norovirus infection group. Phenotype analysis showed that Contains_Mobile_Elements had the highest level of phenotypes in the gut microbiota of norovirus infection. Norovirus infection may lead to dysregulation of the gut microbiome in children.
DOI: 10.6084/m9.figshare.25209585
title: Efficacy of intraoperative systemic lidocaine on quality of recovery after laparoscopic colorectal surgery: a randomized controlled trial

description: Many clinical trials have demonstrated the benefits of intraoperative systemic lidocaine administration in major abdominal surgeries. We tested the hypothesis that systemic lidocaine is associated with an enhanced early quality of recovery in patients following laparoscopic colorectal resection. We randomly allocated 126 patients scheduled for laparoscopic colorectal surgery in a 1:1 ratio to receive either lidocaine (1.5 mg kg<sup>−1</sup> bolus over 10 min, followed by continuous infusion at 2 mg kg<sup>−1</sup> h<sup>−1</sup> until the end of surgery) or identical volumes and rates of saline. The primary outcome was the Quality of Recovery-15 score assessed 24 h after surgery. Secondary outcomes were areas under the pain numeric rating scale curve over time, 48-h morphine consumption, and adverse events. Compared with saline, systemic lidocaine improved the Quality of Recovery-15 score 24 h postoperatively, with a median difference of 4 (95% confidence interval: 1–6; <i>p</i> = 0.015). Similarly, the area under the pain numeric rating scale curve over 48 h at rest and on movement was reduced in the lidocaine group (<i>p</i> = 0.004 and <i>p</i> &lt; 0.001, respectively). However, these differences were not clinically meaningful. Lidocaine infusion reduced the intraoperative remifentanil requirements but not postoperative 48-h morphine consumption (<i>p</i> &lt; 0.001 and <i>p</i> = 0.34, respectively). Additionally, patients receiving lidocaine had a quicker and earlier return of bowel function, as indicated by a shorter time to first flatus (log-rank <i>p</i> &lt; 0.001), yet ambulation time was similar between groups (log-rank test, <i>p</i> = 0.11). In patients undergoing laparoscopic colorectal surgery, intraoperative systemic lidocaine resulted in statistically but not clinically significant improvements in quality of recovery (see Graphical Abstract). <b><i>Trial registration</i>:</b> Chinese Clinical Trial Registry; ChiCTR1900027635. Systemic lidocaine failed to clinically improve the overall quality of recovery following laparoscopic colorectal resection.Systemic lidocaine reduced intraoperative remifentanil and time to first flatus but not postoperative 48-h morphine consumption.No differences emerged in patient-reported outcomes like opioid side effects, mobility, or satisfaction between groups postoperatively. Systemic lidocaine failed to clinically improve the overall quality of recovery following laparoscopic colorectal resection. Systemic lidocaine reduced intraoperative remifentanil and time to first flatus but not postoperative 48-h morphine consumption. No differences emerged in patient-reported outcomes like opioid side effects, mobility, or satisfaction between groups postoperatively.
DOI: 10.6084/m9.figshare.25209585.v1
title: Efficacy of intraoperative systemic lidocaine on quality of recovery after laparoscopic colorectal surgery: a randomized controlled trial

description: Many clinical trials have demonstrated the benefits of intraoperative systemic lidocaine administration in major abdominal surgeries. We tested the hypothesis that systemic lidocaine is associated with an enhanced early quality of recovery in patients following laparoscopic colorectal resection. We randomly allocated 126 patients scheduled for laparoscopic colorectal surgery in a 1:1 ratio to receive either lidocaine (1.5 mg kg<sup>−1</sup> bolus over 10 min, followed by continuous infusion at 2 mg kg<sup>−1</sup> h<sup>−1</sup> until the end of surgery) or identical volumes and rates of saline. The primary outcome was the Quality of Recovery-15 score assessed 24 h after surgery. Secondary outcomes were areas under the pain numeric rating scale curve over time, 48-h morphine consumption, and adverse events. Compared with saline, systemic lidocaine improved the Quality of Recovery-15 score 24 h postoperatively, with a median difference of 4 (95% confidence interval: 1–6; <i>p</i> = 0.015). Similarly, the area under the pain numeric rating scale curve over 48 h at rest and on movement was reduced in the lidocaine group (<i>p</i> = 0.004 and <i>p</i> &lt; 0.001, respectively). However, these differences were not clinically meaningful. Lidocaine infusion reduced the intraoperative remifentanil requirements but not postoperative 48-h morphine consumption (<i>p</i> &lt; 0.001 and <i>p</i> = 0.34, respectively). Additionally, patients receiving lidocaine had a quicker and earlier return of bowel function, as indicated by a shorter time to first flatus (log-rank <i>p</i> &lt; 0.001), yet ambulation time was similar between groups (log-rank test, <i>p</i> = 0.11). In patients undergoing laparoscopic colorectal surgery, intraoperative systemic lidocaine resulted in statistically but not clinically significant improvements in quality of recovery (see Graphical Abstract). <b><i>Trial registration</i>:</b> Chinese Clinical Trial Registry; ChiCTR1900027635. Systemic lidocaine failed to clinically improve the overall quality of recovery following laparoscopic colorectal resection.Systemic lidocaine reduced intraoperative remifentanil and time to first flatus but not postoperative 48-h morphine consumption.No differences emerged in patient-reported outcomes like opioid side effects, mobility, or satisfaction between groups postoperatively. Systemic lidocaine failed to clinically improve the overall quality of recovery following laparoscopic colorectal resection. Systemic lidocaine reduced intraoperative remifentanil and time to first flatus but not postoperative 48-h morphine consumption. No differences emerged in patient-reported outcomes like opioid side effects, mobility, or satisfaction between groups postoperatively.
DOI: 10.6084/m9.figshare.27635889
title: AVG delamination: a cause of early cannulation arteriovenous graft dysfunction in hemodialysis patients

description: A series of cases have reported graft delamination as a rare complication of early-cannulation arteriovenous graft (ecAVG). The unique multilayer structure of ecAVGs contributes to the property of cannulation as early as hours after implantation, but on other hand it takes the risk of graft delamination. However, the underlying mechanism and management of graft delamination as well as its effects on the long-term patency of ecAVGs have not been systemically analyzed. A retrospective study was conducted in a cohort of patients who required an ecAVG for hemodialysis (HD) access in our center between April 2017 and December 2021. The characteristics of graft delamination and the outcomes of its different treatments were analyzed. A total of 144 ecAVGs were established in 141 end-stage renal disease (ESRD) patients, including 124 (86.1%) Acuseal grafts and 20 (13.9%) Flixene grafts. During follow-up 24.5(11.5, 45.8) months, 11 (7.6%) subjects had graft infection with an incidence of 0.03 patient-year. Thirteen (9.0%) subjects had graft delamination at 9.3(5.0,12.4) months after ecAVG implantation, with an incidence of 0.04 per patient-year. ecAVG delamination was observed in both Acuseal grafts (0.037 per patient-year) and Flixene grafts (0.055 per patient-year). Thrombosis or venous hypertension was the most common complaints. Seven delamination was observed at 1.3 (0.1, 4.2) months after an endovascular procedure. The primary patency, primary assistant patency and secondary patency in delamination group were significantly lower than that in non-delamination group (<i>p</i> &lt; 0.05). Post-procedure primary patency of group A (percutaneous transluminal angioplasty, PTA), group B (stenting) and group C (partial graft replacement, PGR) were 1.3 (0.45,4.22) months, 5.3 (3.05,6.85) months and 8.45 (4.78,14.53) months respectively (<i>p</i> = 0.029). Graft delamination was not a rare complication of ecAVGs in this cohort. It significantly reduced the long-term patency of AVGs. PGR might be a more effective therapeutic way than endovascular treatments.
DOI: 10.6084/m9.figshare.27635889.v1
title: AVG delamination: a cause of early cannulation arteriovenous graft dysfunction in hemodialysis patients

description: A series of cases have reported graft delamination as a rare complication of early-cannulation arteriovenous graft (ecAVG). The unique multilayer structure of ecAVGs contributes to the property of cannulation as early as hours after implantation, but on other hand it takes the risk of graft delamination. However, the underlying mechanism and management of graft delamination as well as its effects on the long-term patency of ecAVGs have not been systemically analyzed. A retrospective study was conducted in a cohort of patients who required an ecAVG for hemodialysis (HD) access in our center between April 2017 and December 2021. The characteristics of graft delamination and the outcomes of its different treatments were analyzed. A total of 144 ecAVGs were established in 141 end-stage renal disease (ESRD) patients, including 124 (86.1%) Acuseal grafts and 20 (13.9%) Flixene grafts. During follow-up 24.5(11.5, 45.8) months, 11 (7.6%) subjects had graft infection with an incidence of 0.03 patient-year. Thirteen (9.0%) subjects had graft delamination at 9.3(5.0,12.4) months after ecAVG implantation, with an incidence of 0.04 per patient-year. ecAVG delamination was observed in both Acuseal grafts (0.037 per patient-year) and Flixene grafts (0.055 per patient-year). Thrombosis or venous hypertension was the most common complaints. Seven delamination was observed at 1.3 (0.1, 4.2) months after an endovascular procedure. The primary patency, primary assistant patency and secondary patency in delamination group were significantly lower than that in non-delamination group (<i>p</i> &lt; 0.05). Post-procedure primary patency of group A (percutaneous transluminal angioplasty, PTA), group B (stenting) and group C (partial graft replacement, PGR) were 1.3 (0.45,4.22) months, 5.3 (3.05,6.85) months and 8.45 (4.78,14.53) months respectively (<i>p</i> = 0.029). Graft delamination was not a rare complication of ecAVGs in this cohort. It significantly reduced the long-term patency of AVGs. PGR might be a more effective therapeutic way than endovascular treatments.
DOI: 10.6084/m9.figshare.26879609
title: Combining host immune response biomarkers and clinical scores for early prediction of sepsis in infection patients

description: The performance of host immune responses biomarkers and clinical scores was compared to identify infection patient populations at risk of progression to sepsis, ICU admission and mortality. Immune response biomarkers were measured and NEWS, SIRS, and MEWS. Logistic and Cox regression models were employed to evaluate the strength of association. IL-10 and NEWS had the strongest association with sepsis development, whereas IL-6 and CRP had the strongest association with ICU admission and in-hospital mortality. IL-6 [HR (95%CI) = 2.68 (1.61–4.46)] was associated with 28-day mortality. Patient subgroups with high IL-10 (≥ 5.03 pg/ml) and high NEWS (&gt; 5 points) values had significantly higher rates of sepsis development (88.3% vs 61.1%; <i>p</i> &lt; 0.001), in-hospital mortality (35.0% vs. 16.7%; <i>p</i> &lt; 0.001), 28-day mortality (25.0% vs. 5.6%; <i>p</i> &lt; 0.001), and ICU admission (66.7% vs. 38.9%; <i>p</i> &lt; 0.001). Patients exhibiting low severity signs of infection but high IL-10 levels showed an elevated probability of developing sepsis. Combining IL-10 with the NEWS score provides a reliable tool for predicting the progression from infection to sepsis at an early stage. Utilizing IL-6 in the emergency room can help identify patients with low NEWS or SIRS scores.
DOI: 10.6084/m9.figshare.26879609.v1
title: Combining host immune response biomarkers and clinical scores for early prediction of sepsis in infection patients

description: The performance of host immune responses biomarkers and clinical scores was compared to identify infection patient populations at risk of progression to sepsis, ICU admission and mortality. Immune response biomarkers were measured and NEWS, SIRS, and MEWS. Logistic and Cox regression models were employed to evaluate the strength of association. IL-10 and NEWS had the strongest association with sepsis development, whereas IL-6 and CRP had the strongest association with ICU admission and in-hospital mortality. IL-6 [HR (95%CI) = 2.68 (1.61–4.46)] was associated with 28-day mortality. Patient subgroups with high IL-10 (≥ 5.03 pg/ml) and high NEWS (&gt; 5 points) values had significantly higher rates of sepsis development (88.3% vs 61.1%; <i>p</i> &lt; 0.001), in-hospital mortality (35.0% vs. 16.7%; <i>p</i> &lt; 0.001), 28-day mortality (25.0% vs. 5.6%; <i>p</i> &lt; 0.001), and ICU admission (66.7% vs. 38.9%; <i>p</i> &lt; 0.001). Patients exhibiting low severity signs of infection but high IL-10 levels showed an elevated probability of developing sepsis. Combining IL-10 with the NEWS score provides a reliable tool for predicting the progression from infection to sepsis at an early stage. Utilizing IL-6 in the emergency room can help identify patients with low NEWS or SIRS scores.
DOI: 10.6084/m9.figshare.27210757
title: Prognostic value of [<sup>18</sup>F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study

description: This retrospective study aimed to evaluate the prognostic value of [<sup>18</sup>F]FDG parameters in patients with visceral and bone metastatic hormone-sensitive prostate cancer (mHSPC). This analysis included the mHSPC patients who underwent [<sup>18</sup>F]FDG PET/CT at the initial diagnosis. Baseline characteristics were analyzed, and the uptake of [<sup>18</sup>F]FDG was quantified using SUV<sub>max</sub>. Kaplan–Meier and Cox proportional hazard regression analysis were employed to evaluate the correlation between SUV<sub>max</sub> and patient survival. Among the 267 patients enrolled, 90 (33.7%) presented with visceral metastases and 177 (66.3%) had bone metastases. The median follow-up for the visceral metastasis group was 35.5 months (IQR 26–53.8 months). The median overall survival for patients with lung, liver, or both metastases were 30, 21 and 17 months, respectively. Patients exhibiting higher [<sup>18</sup>F]FDG uptake in metastatic lesions experienced shorter overall survival (OS) in comparison to those with lower [<sup>18</sup>F]FDG uptake, both in the visceral metastases group (17 vs. 31 months, <i>p</i> = 0.002) and the bone metastases group (27.5 vs. 34.5 months, <i>p</i> &lt; 0.001). Cox regression analysis further revealed that increased [<sup>18</sup>F]FDG uptake in metastatic lesions emerged as a significant risk factor in both OS and progression-free survival (PFS). In contrast, the variability in [<sup>18</sup>F]FDG uptake in primary lesions did not provide a reliable indicator for predicting prognosis. In mHSPC patients, higher [<sup>18</sup>F]FDG uptake in metastatic lesions indicates shorter survival and increased risk of disease progression. The [<sup>18</sup>F]FDG SUV<sub>max</sub> in primary tumors did not show significant prognostic value. Our study underscores the unique prognostic potential of [<sup>18</sup>F]FDG PET/CT in mHSPC patients, highlighting its importance in the management of both bone and visceral metastases.
DOI: 10.6084/m9.figshare.27290512
title: Combined miRNA transcriptome and proteome analysis of extracellular vesicles in urine and blood from the Pompe mouse model

description: Acid α-glucosidase (GAA) is a lysosomal enzyme that hydrolyzes glycogen to glucose. Deficiency of GAA causes Pompe disease (PD), also known as glycogen storage disease type II. The resulting glycogen accumulation causes a spectrum of disease severity ranging from infantile-onset PD to adult-onset PD. Additional non-invasive biomarkers of disease severity are needed to monitor response to therapeutic interventions. We measured protein and miRNA abundance in exosomes from serum and urine from the PD mouse model (B6;129-GaaTm1Rabn/J), wild-type mice, and PD mice treated with a candidate gene therapy. There were significant differences in the abundance of 113 miRNA in serum exosomes from Pompe versus healthy mice. Levels of miR-206, miR-133, miR-1a, miR-486, and other important regulators of muscle development and maintenance were altered in the Pompe samples. The serum and urine exosome proteomes of healthy and Pompe mice also differed broadly. Several of the dysregulated proteins are encoded by genes with potential target sites for affected miRNA. Exosomes derived from urine or serum are a potential source of biomarkers for Pompe Disease. Further study of the differences in the miRNA transcriptome and proteome content of exosomes may yield new insights into disease mechanisms.
DOI: 10.6084/m9.figshare.27290512.v1
title: Combined miRNA transcriptome and proteome analysis of extracellular vesicles in urine and blood from the Pompe mouse model

description: Acid α-glucosidase (GAA) is a lysosomal enzyme that hydrolyzes glycogen to glucose. Deficiency of GAA causes Pompe disease (PD), also known as glycogen storage disease type II. The resulting glycogen accumulation causes a spectrum of disease severity ranging from infantile-onset PD to adult-onset PD. Additional non-invasive biomarkers of disease severity are needed to monitor response to therapeutic interventions. We measured protein and miRNA abundance in exosomes from serum and urine from the PD mouse model (B6;129-GaaTm1Rabn/J), wild-type mice, and PD mice treated with a candidate gene therapy. There were significant differences in the abundance of 113 miRNA in serum exosomes from Pompe versus healthy mice. Levels of miR-206, miR-133, miR-1a, miR-486, and other important regulators of muscle development and maintenance were altered in the Pompe samples. The serum and urine exosome proteomes of healthy and Pompe mice also differed broadly. Several of the dysregulated proteins are encoded by genes with potential target sites for affected miRNA. Exosomes derived from urine or serum are a potential source of biomarkers for Pompe Disease. Further study of the differences in the miRNA transcriptome and proteome content of exosomes may yield new insights into disease mechanisms.